Literature DB >> 17297307

c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.

Antje Menssen1, Alexey Epanchintsev, Dmitri Lodygin, Nousin Rezaei, Peter Jung, Berlinda Verdoodt, Joachim Diebold, Heiko Hermeking.   

Abstract

Here we show that the human BubR1 and MAD2 genes, which encode inhibitors of the anaphase promoting complex (APC/C), are directly activated by the oncogenic transcription factor c-MYC via E-box sequences in their first introns. In colorectal cancer biopsies elevated expression of c-MYC correlated with increased MAD2 levels. Activation of a conditional c-MYC allele delayed progression through mitosis in pro-metaphase in a MAD2- and BubR1-dependent manner. A fraction of the daughter cells derived from extended mitotic events underwent synchronous apoptosis, which was in part mediated by BubR1. Furthermore, c-MYC activation resulted in CIN (chromosomal instability) in the diploid MIN (microsatellite instability) cell line DLD-1 and further enhanced CIN in the aneuploid CIN-line MCF7. Unexpectedly, c-MYC-induced CIN was independent of c-MYC-induced BubR1/MAD2 expression and mitotic delay. Therefore, c-MYC-induced CIN may be caused be alternative pathways. We observed that activation of c-MYC induced DNA double-strand breaks, as evidenced by formation of gamma-H2AX foci, which colocalized with foci of active DNA replication. Furthermore, c-MYC activation resulted in mitotic chromosomes exhibiting DNA damage. Therefore, oncogenic deregulation of c-MYC prevents repair of replication-stress induced DNA lesions in the G(2)-phase. We suggest that the c-MYC-mediated persistence of DNA lesions throughout mitosis leads to chromosomal missegregation and underlies c-MYC-induced CIN. The effects of deregulated c-MYC on progression through mitosis described here may have important implications for the origin of chromosomal instability in many tumor types and the sensitivity towards cancer therapeutic agents targeting DNA or the mitotic spindle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297307     DOI: 10.4161/cc.6.3.3808

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  45 in total

1.  AP4 encodes a c-MYC-inducible repressor of p21.

Authors:  Peter Jung; Antje Menssen; Doris Mayr; Heiko Hermeking
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

Review 2.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

4.  MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Authors:  Christof Schneider; Manu Setty; Antony B Holmes; Roy L Maute; Christina S Leslie; Lara Mussolin; Angelo Rosolen; Riccardo Dalla-Favera; Katia Basso
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

5.  Hematopoietic PBX-interacting protein is a substrate and an inhibitor of the APC/C-Cdc20 complex and regulates mitosis by stabilizing cyclin B1.

Authors:  Saratchandra Singh Khumukcham; Venkata Subramanyam Kumar Samanthapudi; Vasudevarao Penugurti; Anita Kumari; P S Kesavan; Loka Reddy Velatooru; Siva Reddy Kotla; Aprotim Mazumder; Bramanandam Manavathi
Journal:  J Biol Chem       Date:  2019-05-17       Impact factor: 5.157

6.  Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.

Authors:  Daniel Henry Marks; Rozario Thomas; Yvette Chin; Riddhi Shah; Christine Khoo; Robert Benezra
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

Review 7.  Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer.

Authors:  W Brian Dalton; Vincent W Yang
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

8.  MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.

Authors:  Giuliana Gatti; Giovanna Maresca; Manuela Natoli; Fulvio Florenzano; Angelo Nicolin; Armando Felsani; Igea D'Agnano
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

9.  [c-MYC-mediated regulations in colorectal cancer].

Authors:  A Menssen
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

10.  Smurf2 as a novel mitotic regulator: From the spindle assembly checkpoint to tumorigenesis.

Authors:  Evan C Osmundson; Dipankar Ray; Finola E Moore; Hiroaki Kiyokawa
Journal:  Cell Div       Date:  2009-07-07       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.